US Patent

US8609647 — Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

Method of Use · Assigned to Japan Tobacco Inc · Expires 2031-09-19 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound and its pharmaceutical uses, including treating organ transplant rejection and autoimmune diseases.

USPTO Abstract

A compound of the following general formula [I]: wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4237 — Corectim

Patent Metadata

Patent number
US8609647
Jurisdiction
US
Classification
Method of Use
Expires
2031-09-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Japan Tobacco Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.